Table 4.
Tranexamic acid (TA) use (alone or with FR therapy) in the 207 surgical procedures.
| Severe deficiencies (coagulation factor level ≤10%) | ||||||
|---|---|---|---|---|---|---|
| Factor deficiency | TA/ all procedures (%) | All procedures |
TA alone/ procedures without FR (%) | TA/ all procedures at HFS (%) | High fibrinolytics sites (HFS) |
TA alone/ procedures at HFS without FR (%) |
| TA and FR/ treated procedures (%) | TA and FR/ treated procedures at HFS (%) | |||||
| FVII | 17/51 (33) | 9/39 | 8/12 | 9/11 | 3/5 | 6/6 |
| FXI | 13/24 (54) | 4/11 | 9/13 | 3/4 | 0/1 | 3/3 |
| FV | 1/1 (100) | 0 | 1/1 | 0/1 | 0 | 0/1 |
| FV+FVIII | 2/2 (100) | 2/2 | 0 | 1/1 | 1/1 | 0 |
| FX | 1/3 (33) | 0/2 | 1/1 | 1/1 | 1/1 | 0 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 34/81 (42) | 15/54 (28) | 18/27 (66) | 14/18 (78) | 5/8 (62) | 9/10 (90) |
| Mild deficiencies (coagulation factor level >10%) | ||||||
|---|---|---|---|---|---|---|
| Factor deficiency | TA/ all procedures (%) | All procedures |
TA alone/ procedures without FR (%) | TA/ all procedures at HFS (%) | HFS |
TA alone/ procedures without FR (%) |
| TA and FR/ treated procedures (%) | TA and FR/ treated procedures at HFS (%) | |||||
| FVII | 24/67 (36) | 3/15 | 21/52 | 13/21 | 2/2 | 11/19 |
| FXI | 25/40 (62) | 4/8 | 21/32 | 12/12 | 1/1 | 11/11 |
| FV | 4/13 (30) | 0 | 4/13 | 3/4 | 0/0 | 3/4 |
| FV+FVIII | 1/1 (100) | 0 | 1/1 | 1/1 | 0/0 | 1/1 |
| FX | 0/4 (0) | 0/3 | 0/1 | 0 | 0 | 0 |
| FII | 0/1 (0) | 0 | 0/1 | 0 | 0 | 0 |
| Total | 54/126 (43) | 7/26 (27) | 47/100 (47) | 29/38 (76) | 3/3 (100) | 26/35 (74) |
FR, factor replacement; HFS, high fibrinolytics sites; TA, Tranexamic acid.